Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: A comparison with healthy volunteers

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 309-313

  Turck D ^a   Schwarz, A ^b   Hoffler D ^b   Narjes, H H ^a   Nehmiz, G ^a   Heinzel, G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b Städtische Klinken   (Germany)

Author keywords

End stage renal failure; Meloxicam; haemodialysis; Pharmacokinetic

Indexed keywords

MELOXICAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; THIAZINES; THIAZOLES;

EID: 0030444355     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050203     Document Type: Article

References (23)

1. Al-Ghamdi, Al-Mohanna FA, Al-Mustafa AZ, Al-Saeed IS (1992) The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. Eur J Clin Pharmacol 43:197-199
2. Anttila M, Haataja M, Kasanen A (1980) Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 18:263-268
3. Brater DC, Lasseter KC (1989) Profile of etodolac: pharmacokinetic evaluation in special populations, Clin Rheumatol 98 [Suppl 1]:25-35
4. Boobis SW (1977) Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 22: 147-53
5. Brier ME, Sloan RS, Aronoff GR (1995) Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clin Pharmacol Ther 57:622-627
6. Distel M, Bluhmki E (1995) Global analysis of safety of meloxicam, a new enolic acid derived non-steroidal anti-inflammatory agent. Rheumatol Eur 24 [Suppl 3]:390
7. Engelhardt G (1994) Meloxicam: A potent inhibitor of COX-2. Data presented at 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, p 82
8. Engelhardt G, Bögel R, Schnitzler Chr, Utzmann R (1996) Meloxicam: Influence on arachidonic acid metabolism. Part II, in vivo findings. Biochem Pharmacol 51:29-38
9. Frocht A, Fillit H (1984) Renal disease in the geriatric patient. J Am Ger Soc 32:28-43
10. Gwilt PR, Perrier D (1978) Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther 24:154-161
11. Guralnik JM, LaCroix AZ, Everett DF, Kovar MG (1989) Aging in the eighties: the prevalence of comorbidity and its association with disability. Vital and Health Statistics of the National Center for Health Center for Statistics. Advance Data Rep 170:1-8
12. Heinzel G, Woloszczak R, Thomann P (1993) Topfit 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart
13. Lin JH, Cocchetto DM, Duggan DE (1987) Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12:402-432
14. Mitchell JA, Akarasereemont P, Thiemermann Chr, Flower RJ, Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697
15. Rogers HJ, Savitsky JP, Glenn B, Spector RE (1981) Kinetics of single doses of Penbufen in patients with renal insufficiency. Clin Pharmacol Ther 29:74-80
16. Sjöholm I, Kober A, Odar-Cederlof I, Borga O (1976) Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 25: 1205-1213
17. Türck D, Boulton-Jones JM, North N, Heinzel G, Nehmiz G (1995a) Determination of the steady-state pharmacokinetics of meloxicam 15 mg once daily in subjects with mild, moderate or no renal impairment. Rheumatol Eur 24 [Suppl 3]:221
18. Türck D, Busch U, Heinzel E, Narjes H, Nehmiz G (1995b) Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 9:270-276
19. Türck D, Roth W, Busch U (1996) A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 35 [Suppl 1]:13-16
20. Verbeeck RK, DeSchepper PJ (1980) Influence of chronic renal failure and hemodialysis on diflunisal protein binding. Clin Pharmacol Ther 27:628-635
21. Verbeeck RK, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8:297-331
22. Weber SS, Troutman WG, Trujeque L (1979) Effect of hemodialysis on plasma naproxen concentration. Am J Hosp Pharm 36:1567-1569
23. Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390